Pregnancy and Chronic Myeloid Leukemia

Öz

Chronic myeloid leukemia (CML) is a myeloproliferative disease characterized by monoclonal proliferation of hematopoietic stem cells in the bone marrow. CML is extremely rare in pregnancy, with an estimated annual incidence of 1 in 100,000 pregnancies. CML is less than 10% of leukemias seen in pregnancy. The treatment and care process of leukemia during pregnancy is extremely important in terms of maternal and infant health. The aim of this study was to evaluate the importance of nursing care of pregnant women with leukemia and to develop awareness of more effective nursing care. Healthy live birth was performed under CML treatment. Pregnancy and pospartum nursing care were performed.

Anahtar Kelimeler

• : Leukemia
• Pregnancy
• Nursing Care

Gebelik ve Kronik Miyeloid Lösemi

Öz

Kronik miyeloid lösemi (KML), kemik iliğindeki hematopoietik kök hücrelerin monoklonal çoğalmasıyla karakterize myeloproliferatif bir hastalıktır. Gebelikte KML oldukça nadir görülür, tahmin edilen yıllık insidansı 100.000 gebelikte 1’dir. KML gebelikte görülen lösemilerin %10’undan azını oluşturur. Gebelikte löseminin tedavi ve bakım süreci, anne ve bebek sağlığı açısından son derece önemlidir. Lösemili gebe olguların hemşirelik bakımının önemine dikkat çekmek ve daha etkin bir hemşirelik bakımına ilişkin farkındalık oluşturmak amacı ile 27 yaşında, 5 aylık gebe, KML tanılı olgu ele alındı. KML tedavisi altında sağlıklı canlı doğum yaptırıldı. Gebelik ve pospartum hemşirelik bakımı gerçekleştirildi.

Anahtar Kelimeler

• Lösemi
• gebelik
• hemşirelik bakımı

Kaynakça

1. 1.Fialkow P, Jacobson R, Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med. 1977;63(1):125-130.
2. 2.Yadav U, Solanki SL, Yadav R. Chronic myeloid leukemia with pregnancy: Successful management of pregnancy and delivery with hydroxyurea and imatinib continued till delivery.J Cancer Res Ther. 2013;9(3):484-486. doi:10.4103/0973-1482.119305
3. 3.Scheffler M, Di Gion P, Doroshyenko O, Wolf J, Fuhr U.Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines. Clin Pharmacokinet. 2011;50(6):371-403.
4. 4.Ali R, Özkalemkas F, Özkocaman V, et al. Successful pregnancy and delivery in a patient with chronic myeloidleukemia: a case report and review of the literature. Springerplus. 2016;5(1):215-217. doi:10.1186/s40064-016-3693-0
5. 5.Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966-984. doi:10.1038/s41375-020-0776-2
6. 6.Takahashi N, Miura M. Therapeutic drug monitoring of imatinib for chronic myeloid leukemia patients in the chronic phase. Pharmacology. 2011;87(5-6):241-248. doi:10.1159/000324900
7. 7.www.novartis.com.tr/sites/17.03.2020. Glivec product information.
8. 8.Hensley ML, Ford JM. Imatinib treatment: Specific issues related to safety, fertility, and pregnancy. Semin Hematol. 2003;40(2 SUPPL. 2):21-25. doi:10.1053/shem.2003.50038

9. 9.Madabhavi I, Sarkar M, Modi M, Kadakol N. Pregnancy outcomes in chronic myeloid leukemia: a single centerexperience. . J Glob Oncol. 2019;5:1-11.
10. 10.Pye S, Cortes J, Ault P, et al. The effects of imatinib onpregnancy outcome. Blood. 2008;111(12):5505-5508.
11. 11.Ali R, Ozkalemkas F, Ozcelik T, Ozkocaman V, Ozkan A. Imatinib and pregnancy [5]. J Clin Oncol. 2006;24(23):3812-3813. doi:10.1200/JCO.2006.06.9310
12. 12.Prabhash K, Sastry P, Biswas G, et al. Pregnancy outcome oftwo patients treated with imatinib. Ann Oncol. 2005;16(12):1983-1984.
13. 13.Türk Hematoloji Derneği. Kronik myeloid lösemi (KML) tanı ve tedavi kılavuzu. Türk Hematol Derneği. Published online 2016:1-20. http://www.thd.org.tr/thdData/Books/69/bolum-i-kronik-miyeloid-losemi-kml.pdf
14. 14.Dittner AJ, Wessely SC, Brown RG. The assessment of fatigue:A practical guide for clinicians and researchers. J PsychosomRes. 2004;56(2):157-170. doi:10.1016/S0022-3999(03)00371-4
15. 15.Ugur O. Symptom management of cancer patients. Turkish JOncol. 2014;29(3):125-135. doi:10.5505/tjoncol.2014.1077
16. 16.Salem W, Li K, Krapp C, et al. Imatinib treatments have long-term impact on placentation and embryo survival. Sci Rep. 2019;9(1):1-10. doi:10.1038/s41598-019-39134-0
17. 17.Can G. Kanser hastasında yorgunluk. HEMARGE. 2006;3(2):10-17.
18. 18.Çalışkan E, Gürhan N, Tekgündüz AİE. Distress, anxiety anddepression in patients who have received hematologic cancer diagnosis. Acta Oncol Turc. 2017;50(3):207-217. doi:10.5505/aot.2017.70298
19. 19.Arslan B, Arslan A, Kara S, Öngel K, Mungan MT. Risk factors for pregnancy anxiety and depression: assessment in452 cases. J Tepecik Educ Res Hosp. 2011;21(2):79-84. doi:10.5222/terh.2011.45398
20. 20.Zaman F, Özkan N, Toprak D. Gebelikte depresyon veanksiyete. Konuralp Tıp Derg. 2018;10(1):20-25. doi:10.18521/ktd.311793
21. 21.Özdamar Ö, Yılmaz O, Beyca HH, Muhcu M. Gebelik ve postpartum dönemde sık görülen ruhsal bozukluklar. Zeynep Kamil Tıp Bülteni. 2014;45(2):71-77.
22. 22.Gao M, Sun Y, Xie H, Fang S, Zhao X. Hysteroscopy prior torepeat embryo transfer may improve pregnancy outcomes for asymptomatic women with repeated implantation failure. J ObsGynaecol. 2015;41(10):1569–1576.
23. 23.Park J, Kim S, Oh C, Sung SY, Lee D, Kim Y. Differentialtyrosine phosphorylation of leukemic cells during apoptosis as a result of treatment with imatinib mesylate. Biochem BiophysRes Commun. 2005;336(3):942-951. doi:10.1016/j.bbrc.2005.08.201
24. 24.Ali C. Bir kayıp sonrasında zorluklar yaşayan üniversite öğrencilerine yönelik bir yas danışmanlığı modeli. Mersin Üniversitesi Eğitim Fakültesi Derg. 2006;2(2):0. doi:10.17860/efd.36859
25. 25.Kabaalioglu A. İkinci trimester ultrasonografi incelemesi. Türk Radyoloji Semin. 2017;5(2):202-214. doi:10.5152/trs.2017.505
26. 26.Khalesi ZB, Bokaie M, Attari SM. Effect of pregnancy onsexual function of couples. Afr Health Sci. 2018;18(2):227-234. doi:10.4314/ahs.v18i2.5
27. 27.Schover LR, van der Kaaij M, van Dorst E, Creutzberg C,Huyghe E, Kiserud CE. Sexual dysfunction and infertility aslate effects of cancer treatment. Eur J Cancer, Suppl. 2014;12(1):41-53. doi:10.1016/j.ejcsup.2014.03.004
28. 28.Aygün C, Aygün BK. Gebelik ve konstipasyon. J Inonu UnivMed Fac. 2010;17(1):71-75.
29. 29.Tecen K. Tirozin kinaz inhibitörleri ile tedavi edilen hastalarda tedavi izleminde, ilaç etkileşimleri ve yan etkilerin saptanması ve önlenmesinde klinik eczacının rolü. Published online 2016.
30. 30.Snapper LA, Hart KL, Venkatesh KK, Kaimal AJ, Perlis RH. Cohort study of the relationship between individual psychotherapy and pregnancy outcomes. J Affect Disord. 2018;239(June 2017):253-257. doi:10.1016/j.jad.2018.05.083
31. 31.Martini J, Petzoldt J, Einsle F, Beesdo-baum K, Hö M,Wittchen H. Risk factors and course patterns of anxiety and depressive disorders during pregnancy and after delivery : Aprospective-longitudinal study. 2015;175:385-395. doi:10.1016/j.jad.2015.01.012
32. 32.Aslan Y, Ege E. Breastfeeding self-efficacy of mothers and relationship with depression risk

    Annelerin emzirme öz-yeterliliği ve depresyon riski ile ilişkisi. J Hum Sci. 2016;13(2):3160. doi:10.14687/jhs.v13i2.3759

33. 33.Gunes EF. Anne sütündeki biyoaktif bileşenler. Türkiye KlinBeslenme ve Diyetetik Özel. 2017;3(2):101-110. https://www.researchgate.net/publication/315716309
34. 34.Yılmaz C, Taşpınar A. Doğum sonrası erken dönemde ebeveynlere verilen emzirme eğitiminin bebeklerin ilk altı ay anne sütü alma durumuna etkisi. Gümüşhane Üniversitesi Sağlık Bilim Derg. 2017;6(3):25-34.
35. 35.Bilgen H, Kültürsay N, Türkyılmaz C. Turkish neonatal society guideline on nutrition of the healthy term newborn. Turk Pediatr Ars. 2018;53:S128-S137. doi:10.5152/TurkPediatriArs.2018.01813
36. 36.Clark RE. Tyrosine kinase inhibitor therapy discontinuation for patients with chronic myeloid leukaemia in clinical practice. Curr Hematol Malig Rep. 2019;4:507-514. doi:10.1007/s11899-019-00548-2
37. 37.Savage D, Antman K. Imatinib mesylate--a new oral targetedtherapy. N Engl J Med. 2002;346(9):683-693.
38. 38.Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood. 2007;109:58-60.